Despite ongoing efforts nationwide to reign in drug prices, it doesn’t stop some pharmaceutical companies from launching an already high-priced drug, and then incrementally spiking the prices.
Such is the case for AbbVie’s Humira.
Humira, a drug used to treat a range of conditions, including rheumatoid arthritis, colitis and psoriasis, has doubled in price over the course of six years. The drug in 2012 rang up a $19,000 price tag per patient, according to a New York Times article; today, the treatment costs patients a whopping $38,000.
While former Turing Pharmaceuticals CEO Martin Shkreli’s strategy was to implement huge price hikes (from $13.50 to $750 per pill of Daraprim overnight), others incorporate the more long-term play.
“What they have done with Humira is just as unfair, just as morally wrong, but they did it over five years,” Patients for Affordable Drugs Executive Director Ben Wakana said in an interview. “People are skipping doses, people are rationing, people are going into bankruptcy because of this drug.
AbbVie reportedly declined the New York Times’ request for comment.